Here are three points:
1. In addition to Richard Gorelick, four other Integra LifeSciences executives reported share trades in the last month.
2. The company has a one-year high of $72.05 and a one-year low of $54.75.
3. The company’s consensus rating is “strong buy” and the average price target is $79.67 from all the analysts covering the stock.
More articles on devices:
Spineology releases Palisade Pedicular Fixation System: 4 key notes
Spinal Simplicity invests with Nueterra — 5 notes
Bone Therapeutics completes recruitment for next phase of spinal fusion study: 4 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
